Show simple item record

dc.contributorSpandidos Publ.es_CL
dc.contributor.authorCalaf , G. M. [Chile. Universidad de Tarapacá]es_CL
dc.contributor.authorBadinez, Leonardo [Chile. Instituto Nacional del Cáncer]es_CL
dc.contributor.authorDueñas, Ricardo [Chile. Hospital de Carabineros]es_CL
dc.date.accessioned2018-09-07T14:11:43Z
dc.date.available2018-09-07T14:11:43Z
dc.date.issued2010es_CL
dc.identifier.citationMurray, N. P., Calaf, G. M., Badinez, L., Dueñas, R., Badinez, O., Orellana, N., ... & Fuentealba, C. (2010). P504S expressing circulating prostate cells as a marker for prostate cancer. Oncology reports, 24(3), 687-692.es_CL
dc.identifier.issnISSN 1021-335Xes_CL
dc.identifier.issnESSN 1791-2431es_CL
dc.identifier.urihttps://www.spandidos-publications.com/or/24/3/687/downloades_CL
dc.identifier.urihttps://doi.org/10.3892/or_00000908es_CL
dc.identifier.urihttp://repositorio.umayor.cl/xmlui/handle/sibum/2751
dc.description.abstractProstate cancer is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths. The serum prostate specific antigen (PSA) is the only biomarker routinely used in screening. The aim of this study was to develop a system to test the presence of circulating prostate cells in men without a diagnosis of prostate cancer in relation with age, serum PSA levels and prostate biopsy by determining the co-expression of several markers such as CD82, HER-2 and matrix metalloproteinase 2 (MMP-2). For this purpose mononuclear cells were separated from blood using differential centrifugation and then prostate cells were identified by using standard immunocytochemical method. Results indicated that among 409 men screened for prostate cancer 16.6% were positive for circulating prostate cells. Cells were positive for MMP-2 and HER-2 in 100 and 14.3% of cases, respectively, without an association with age or PSA levels. However, CD82 protein expression was associated with older age and low grade tumors. It can be concluded that the study of circulating prostate cells with various markers could be a useful complementary screening test for prostate cancer in men with increased PSA level.es_CL
dc.description.sponsorshipEste trabajo fue financiado por Fondecyt 1080482.es_CL
dc.format.extentARTÍCULO ORIGINALes_CL
dc.language.isoenes_CL
dc.publisherCIENCIASes_CL
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chilees_CL
dc.subjectONCOLOGÍAes_CL
dc.titleP504S expressing circulating prostate cells as a marker for prostate canceres_CL
dc.typeArtículo o Paperes_CL
umayor.indizadorCOTes_CL
umayor.politicas.sherpa/romeoLicencia color: BLANCO (El archivo no está formalmente admitido)--Pre-print del autor: el autor no puede archivar la versión pre-print (ie la versión previa a la revisión por pares) Post-print del autor: el autor no puede archivar la versión post-print (ie la versión final posterior a la revisión por pares) Versión de editor/PDF: grey tick el autor puede archivar la versión PDF de la editorial siempre que se cumplan las restricciones: 6 meses de embargo Condiciones generales: La versión de editor/PDF debe utilizarse, On Institutional Repository or Funder's repository, Debe ir enlazado a la versión de editor, La fuente publicada debe reconocerse con la cita completa, Publisher will automatically deposit authors post-print in PubMed Central or Europe PMC after 6 months or 12 months as required by funding agency// Disponible en: http://www.sherpa.ac.uk/romeo/issn/1021-335X/es/es_CL
umayor.indexadoWOSes_CL
dc.identifier.doi10.3892/or_00000908es_CL]
umayor.indicadores.wos-(cuartil)Q3es_CL
umayor.indicadores.scopus-(scimago-sjr)sin informaciónes_CL


Show simple item record